AMSBIO custom CAR-T products enable novel cancer assays on 3D microfluidic platform
AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.
CAR-T cells are genetically modified T-cells used to find and kill cancer cells by targeting specific cancer-associated proteins, or antigens. CAR-T cell therapy is highly effective against haematological malignancies, but faces challenges in solid tumours due to the immunosuppressive effects of the tumour microenvironment. Often, combination therapies, such chemotherapy and checkpoint blockage, are used with CAR-T to improve efficacy.
To investigate CAR-T efficacy, their off-target cytotoxicity and synergistic effects when used in combination assays, UoS and ScreenIn3D researchers developed novel miniaturised screening assays that use very small amounts of CAR-T cells in 3D complex in vitro models of solid tumours on a chip.
This exciting technological advance by UoS and ScreenIn3D researchers is described in detail in a recently published technical article
– see https://bit.ly/3iASDy0
AMSBIO offers a custom service that enables researchers to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various haematological malignancies. Drawing upon its expertise in monoclonal antibody development (rabbit and mouse), AMSBIO can help you design, plan and execute your CAR-T study, whether you are in the preclinical, clinical or proof of concept stage. The AMSBIO CAR-T platform is highly adaptable to your needs and starting materials, allowing you to start with a target molecule (Phase I) or antibody (Phase II). As part of their custom CAR-T development service, AMSBIO construct the single chain variable fragment (ScFv), transfer it into a CAR lentivector of your choice, make lentivirus and transduce activated human (or mouse) T cells. After the CAR-T cells proliferate, the cytotoxicity is measured in a real time assay, CAR expression analysed and cytokine production quantified.